𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Characteristics of compartment-specific bone loss and treatment effects of alendronate in postmenopausal women with fast bone loss using pQCT

✍ Scribed by P.L. Yip; M.W. Yuen; W.Y. Hung; K.S. Leung; W.Y. Choy; S.K. Au; P.C. Leung; Qin Ling

Book ID
116320703
Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
59 KB
Volume
43
Category
Article
ISSN
8756-3282

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Effective inhibition of aromatase inhibi
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole : ZO-FAST study results
✍ Nigel J. Bundred; Ian D. Campbell; Neville Davidson; Richard H. DeBoer; Holger E πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 158 KB

## Abstract ## BACKGROUND. Letrozole is safe and effective in postmenopausal women with estrogen receptor‐positive early breast cancer, but long‐term aromatase inhibitor use may cause bone loss and increase fracture risk. This study evaluated an immediate or delayed strategy of bone protection the

Effects of 1 year of daily teriparatide
Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate
✍ Barbara M Misof; Eleftherios P Paschalis; StΓ©phane Blouin; Nadja Fratzl-Zelman; πŸ“‚ Article πŸ“… 2010 πŸ› American Society for Bone and Mineral Research 🌐 English βš– 163 KB πŸ‘ 1 views

## Abstract Anabolic treatment with teriparatide of postmenopausal osteoporotic patients previously treated with bisphosphonates is a new therapeutic approach. However, its effects on the bone mineralization density distribution (BMDD) are unknown. We studied paired transiliac bone biopsy samples t